Status:
RECRUITING
HRD Tests for Ovarian cancER
Lead Sponsor:
Centre Francois Baclesse
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemothe...
Eligibility Criteria
Inclusion
- Patient aged 18-year or more
- Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \[FIGO\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
- Tumor tissue must be available for HRD analyses (FFPE tissue block) and
- Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
- With sufficient tumour surface area (\> 25 mm²), with a final cellularity of at least 20%
- Patient affiliated to an appropriate social security system
- Patient signed consent form before any trial related activities
Exclusion
- Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Non epithelial or borderline ovarian cancer
- Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
- Exclusive palliative setting
- Patient deprived of liberty or placed under the authority of a tutor
Key Trial Info
Start Date :
February 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2031
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT06152731
Start Date
February 15 2024
End Date
June 1 2031
Last Update
September 17 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens
Amiens, France
2
Centre Francois Baclesse
Caen, France
3
Centre Oscar Lambret
Lille, France
4
Centre Henri Becquerel
Rouen, France